Juno Therapeutics, Inc. (JUNO) Earns “Buy” Rating from Citigroup Inc.

Citigroup Inc. reissued their buy rating on shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) in a research note released on Tuesday, October 31st. The firm currently has a $59.00 price objective on the biopharmaceutical company’s stock.

A number of other research analysts have also commented on the company. Cowen and Company reaffirmed a buy rating and issued a $49.00 price objective on shares of Juno Therapeutics in a report on Friday, October 27th. Maxim Group reaffirmed a buy rating and issued a $56.00 price objective (up from $34.00) on shares of Juno Therapeutics in a report on Monday, October 9th. Goldman Sachs Group, Inc. (The) reaffirmed a neutral rating and issued a $44.00 price objective on shares of Juno Therapeutics in a report on Friday, October 6th. Morgan Stanley reaffirmed an equal weight rating and issued a $43.00 price objective (up from $27.00) on shares of Juno Therapeutics in a report on Friday, October 6th. Finally, Barclays PLC assumed coverage on Juno Therapeutics in a report on Wednesday, September 6th. They issued an overweight rating and a $55.00 price objective on the stock. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the stock. Juno Therapeutics presently has a consensus rating of Hold and a consensus target price of $44.20.

Shares of Juno Therapeutics (NASDAQ:JUNO) opened at $58.64 on Tuesday. Juno Therapeutics has a 12 month low of $17.52 and a 12 month high of $61.59. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77.

Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.07. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The business had revenue of $44.80 million for the quarter, compared to analysts’ expectations of $18.12 million. During the same quarter in the prior year, the business earned ($0.57) EPS. The firm’s revenue for the quarter was up 115.4% on a year-over-year basis. sell-side analysts predict that Juno Therapeutics will post -4.02 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was posted by BBNS and is the property of of BBNS. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://baseballnewssource.com/markets/juno-therapeutics-inc-juno-rating-reiterated-by-citigroup-inc/1747036.html.

In other news, EVP Robert Azelby sold 6,666 shares of the firm’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $54.95, for a total transaction of $366,296.70. Following the completion of the transaction, the executive vice president now directly owns 79,998 shares in the company, valued at $4,395,890.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Richard Klausner sold 12,000 shares of the firm’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $42.66, for a total value of $511,920.00. Following the transaction, the director now owns 783,536 shares of the company’s stock, valued at $33,425,645.76. The disclosure for this sale can be found here. Insiders sold 79,670 shares of company stock valued at $3,553,777 over the last quarter. Corporate insiders own 15.26% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in JUNO. Bank of New York Mellon Corp grew its stake in Juno Therapeutics by 2.8% during the first quarter. Bank of New York Mellon Corp now owns 262,801 shares of the biopharmaceutical company’s stock worth $5,832,000 after purchasing an additional 7,165 shares during the period. UBS Asset Management Americas Inc. grew its stake in Juno Therapeutics by 76.4% during the first quarter. UBS Asset Management Americas Inc. now owns 29,900 shares of the biopharmaceutical company’s stock worth $663,000 after purchasing an additional 12,947 shares during the period. Parametric Portfolio Associates LLC grew its stake in Juno Therapeutics by 88.6% in the first quarter. Parametric Portfolio Associates LLC now owns 39,826 shares of the biopharmaceutical company’s stock valued at $884,000 after acquiring an additional 18,713 shares during the period. JPMorgan Chase & Co. grew its stake in Juno Therapeutics by 2,185.8% in the first quarter. JPMorgan Chase & Co. now owns 62,746 shares of the biopharmaceutical company’s stock valued at $1,393,000 after acquiring an additional 60,001 shares during the period. Finally, Teachers Advisors LLC grew its stake in Juno Therapeutics by 5.8% in the first quarter. Teachers Advisors LLC now owns 64,365 shares of the biopharmaceutical company’s stock valued at $1,428,000 after acquiring an additional 3,531 shares during the period. 66.96% of the stock is owned by institutional investors and hedge funds.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees
Free Agency Season Has Finally Heated Up
Free Agency Season Has Finally Heated Up


Leave a Reply

 
© 2006-2017 BBNS.